Pharmaceuticals News and Research

RSS

Mylan's subsidiary receives FDA approval for GoLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral Solution, USP, the generic version of Braintree Laboratories' GoLytely® laxative.

30 Jan 2010

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.

29 Jan 2010

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.

29 Jan 2010

Derma Sciences implements reverse stock split for trading on NASDAQ Stock Market

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, today announced that it would implement an 8-for-1 reverse split of its issued and outstanding common shares, effective for shareholders of record on February 1, 2010, and a proportional reduction of its authorized common and preferred shares.

29 Jan 2010

IDEXX Laboratories reports revenues for fourth-quarter of 2009

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2009 increased 11% to $270.3 million, from $243.3 million for the fourth quarter of 2008.

29 Jan 2010

Quantrx Biomedical signs agreement to acquire NuRx Pharmaceuticals

QuantRx Biomedical Corporation today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. (OTCBB: NUXP). The transaction is structured as a tax-free, all stock acquisition resulting in a combined company with no debt and a simplified ownership and capital structure.

29 Jan 2010

Best Practices offers tools and resources to build integrated quality systems

Quality in today's business environment has expanded to more than just overseeing production and conducting safety audits.

29 Jan 2010

Contact Solutions' multi-channel solution may help contact centers to improve service and save money

As healthcare companies prepare for a projected increase in contact center traffic, regardless of the outcome of the Obama Administration's healthcare proposals, business leaders are scrambling to ensure they are prepared.

29 Jan 2010

Diamyd Medical announces share capital and total number of shares as of January 29, 2010

As of January 29, 2010, the share capital in Diamyd Medical AB (publ.) is 14 330 494 SEK. The total number of votes is 4 160 187 and the total number of shares is 28 660 988, divided among 1 437 876 shares of series A (1 vote) and 27 223 112 shares of series B (1/10 vote).

29 Jan 2010

Econiche vaccine cited in February, 2010 issue of Scientific American

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that Econiche(TM), the world's first vaccine developed to reduce the shedding by cattle of Escherichia coli (E. coli) O157, has been cited in the February, 2010 issue of Scientific American (Vol. 302, # 2).

29 Jan 2010

Diabetes vaccine: Diamyd Medical to file for market approval in 2011

In her comments in today’s quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical, says that the Company’s objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn’t very far off now.

29 Jan 2010

Collaborative approach will build drug system that works for patients, pharmacies, government

The Alberta Pharmacists' Association (RxA) and the Canadian Association of Chain Drug Stores (CACDS) stated that they strongly support the new pharmacy funding and services model agreement announced today by Alberta Health and Wellness (AHW).

29 Jan 2010

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

The treatment of illness has traditionally been based on the law of averages – what works best for the largest number of patients. As a result, billions of dollars are spent every year on treatments that could be ineffective or even harmful for some patients. What if doctors could tell with a simple test which course of treatment would be best for a particular patient?

From QIAGEN Manchester Limited 29 Jan 2010

Merge Healthcare deploys etrials eDiary 5.0 platform for global urology clinical trial

Merge Healthcare has successfully deployed its etrials eDiary 5.0 platform to conduct a global Phase II urology clinical trial involving 750 patients for one of the largest pharmaceutical companies in the world. Merge was awarded the project because of its eDiary technology, experience in global ePRO (electronic patient reported outcomes) trials and ability to manage the complex logic required by this study. Underway in 22 countries on 3 continents and in 34 languages, the trial also utilizes Merge’s new eDiary Inventory Module to track shipping and supply of study devices in real-time.

29 Jan 2010

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.

29 Jan 2010

Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor

Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance.

29 Jan 2010

AccuDial Pharmaceutical introduces eight new OTC medications in Canada

AccuDial® Pharmaceutical, Inc. delivered a power-packed launch with their new family of eight over-the-counter (OTC) medications in Canada. Colorful floor displays enjoyed prominent placement in every Quebec Walmart pharmacy, and were filled with AccuDial's pain and fever, allergy, and cough and cold pediatric medications.

29 Jan 2010

Tufts CSDD announces the launch of new website

The Tufts Center for the Study of Drug Development, the world's leading, independent authority on the nature and pace of pharmaceutical and biotech drug development, today announced the launch of its new website that makes it easier for industry professionals and others to research critical drug development issues.

29 Jan 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA’s pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyra™.

29 Jan 2010

Pharmaceuticals News and Research

Mylan's subsidiary receives FDA approval for GoLytely laxative

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Derma Sciences implements reverse stock split for trading on NASDAQ Stock Market

IDEXX Laboratories reports revenues for fourth-quarter of 2009

Quantrx Biomedical signs agreement to acquire NuRx Pharmaceuticals

Best Practices offers tools and resources to build integrated quality systems

Contact Solutions' multi-channel solution may help contact centers to improve service and save money

Diamyd Medical announces share capital and total number of shares as of January 29, 2010

Econiche vaccine cited in February, 2010 issue of Scientific American

Diabetes vaccine: Diamyd Medical to file for market approval in 2011

Collaborative approach will build drug system that works for patients, pharmacies, government

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

Merge Healthcare deploys etrials eDiary 5.0 platform for global urology clinical trial

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor

AccuDial Pharmaceutical introduces eight new OTC medications in Canada

Tufts CSDD announces the launch of new website

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence